# Sermorelin References: Published Clinical and Pharmacological Literature > Sermorelin references — the published clinical and pharmacological literature cited across this site, with DOI and PubMed URLs for every primary source. ## Primary Clinical Literature The Sermorelin references on this page are the published source record for every quantitative claim made elsewhere on Medicine Sermorelin. The list is grouped lightly by topical role — foundational mechanism, pediatric clinical trials, pharmacokinetics, adult research, comparative pharmacology, regulatory — but every citation appears in the references_index with its full DOI or PubMed URL. The pediatric clinical record is anchored by the Thorner / international multi-site study group 1996 cohort of 110 prepubertal children with idiopathic GHD [3], the Kirk 1994 idiopathic-short-stature cohort [4], and the Prakash and Goa 1999 review covering both diagnostic and treatment use [6]. The foundational mechanism literature includes the Grossman 1984 clinical pharmacology of GHRH analogs [8], the Thorner-Vance 1988 'Growth hormone, 1988' synthesis [22], and the 2008 GHRH clinical-basic review [7]. The pharmacokinetic record rests on Frohman 1994 for the plasma half-life and clearance measurements [5] and Ishida 2020 for the modern PK-PD synthesis [12]. The Vance 1986 GHRH clinical update established the tachyphylaxis-and-intermittent-dosing mechanism [18]. The adult-research record includes Khorram 1997 [9] and Vittone 1997 [10]. The comparative-pharmacology record includes Raun 1998 for ipamorelin's selective GHS-R1a pharmacology [14], Falutz 2010 for tesamorelin in HIV lipodystrophy [13], Esposito 2003 for PEGylation of GHRH analogs [16], and Ishida 2020 for the combined-stimulus pharmacology [12][15]. Regulatory history is documented in the FDA / RxList the historical FDA-approved branded sermorelin record [17] and contextualized by the Yuen 2019 adult GHD guideline [19], the Ratku 2017 adult-GHD review [20], and the Bartke Endotext GH-in-aging chapter [21]. The references on this site span four decades of work — from the 1984 GHRH-analog clinical pharmacology that first characterized the diagnostic discriminator [8] through the 1980s-1990s pediatric clinical trial program [3][4] and the foundational mechanism reviews [7][22] into the modern comparative-secretagogue pharmacology of Ishida and colleagues [12]. Each citation has been read in its primary form and summarized in the context of the broader Sermorelin record rather than excerpted in isolation. ## Bibliographic Note Citations follow standard biomedical convention with author list, journal, year, and either DOI or PubMed/PMC URL for verification. PubMed PMIDs are reported where available. The complete numbered list appears in the references_index block at the end of this document and is rendered as a structured CollectionPage with ScholarlyArticle items in JSON-LD. Where a citation is referenced multiple times across the site, the marginalia rail notes the pages on which it appears. No proprietary or paywalled sources are cited in preference to open-access alternatives where the latter exist. Where a primary source is paywalled (e.g., older Journal of Clinical Endocrinology & Metabolism articles), the PubMed abstract URL is provided as the verifiable public link. PubMed PMIDs always resolve, even where the underlying full text is restricted. ## How to Read the Sermorelin Literature The Sermorelin literature has three different reading registers, and readers approaching it for the first time benefit from knowing which one a given paper sits in. The pediatric clinical-trial literature is the most narrowly clinical — these are efficacy and safety trials in well-defined patient populations under well-defined dosing regimens, with hard endpoints (height velocity, IGF-1, GH provocative-test response) and standard statistical analyses [3][4][6]. These papers should be read for what they directly measured. The adult-research literature is smaller and more exploratory. Khorram 1997 [9] and Vittone 1997 [10] are biochemical-pharmacology studies in healthy elderly cohorts, characterizing the somatotropic-axis response to nightly GHRH (1-29) dosing. Results are biochemically robust (elevated nocturnal GH, elevated IGF-1) but the clinical endpoints are softer and the cohorts are smaller. Read for axis response, not as evidence of clinical benefit. The mechanism and pharmacology literature is the broadest — Thorner-Vance [7][22], Vance [18], Grossman [8], Frohman [5], Ishida [12][15], Esposito [16], Raun [14] — and is the foundation on which any interpretation of the clinical work rests. The 2008 Thorner et al. review is the canonical clinical-basic synthesis [7]. Read for mechanism first; everything else follows. ## Full Bibliography [1] Sermorelin acetate (GHRH 1-29 NH2) — synthetic 29-amino-acid N-terminal fragment of human growth hormone-releasing hormone; molecular weight 3357.9 Da; sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Reference compound characterization, drug monograph. — https://www.rxlist.com/sermorelin-acetate-drug.htm [2] Mechanism note: GHRH receptor (GHRHR) is a class B G-protein-coupled receptor on anterior pituitary somatotrophs; activation couples to Gs-alpha / adenylyl cyclase / cAMP / PKA, driving GH gene transcription, synthesis, and pulsatile release; hepatic IGF-1 induction is downstream of GH. See Thorner et al., 2008 (citation 7) for the canonical mechanism synthesis. — https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01740.x [3] Thorner MO, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. international multi-site study group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. — https://pubmed.ncbi.nlm.nih.gov/8772599/ [4] Kirk JM, Trainer PJ, Majrowski WH, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. J Clin Endocrinol Metab. 1994;79(4):1248-1252. — https://pubmed.ncbi.nlm.nih.gov/7955460/ [5] Frohman LA, Downs TR, Heimer EP, Felix AM. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. — https://pubmed.ncbi.nlm.nih.gov/7962295/ [6] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. — https://pubmed.ncbi.nlm.nih.gov/18031173/ [7] Thorner MO, Vance ML, Hartman ML, et al. Growth-hormone-releasing hormone: clinical and basic studies. J Neuroendocrinol. 2008. — https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01740.x [8] Grossman A, Savage MO, Lytras N, Preece MA, Sueiras-Diaz J, Coy DH, Rees LH, Besser GM. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol (Oxf). 1984. — https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2265.1984.tb03477.x [9] Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. — https://pubmed.ncbi.nlm.nih.gov/9100610/ [10] Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. — https://pubmed.ncbi.nlm.nih.gov/9226107/ [11] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development (companion review). — https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [12] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020. — https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [13] Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010. — https://pubmed.ncbi.nlm.nih.gov/20660039/ [14] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. — https://www.semanticscholar.org/paper/Ipamorelin-the-first-selective-growth-hormone-Raun-Hansen/67208f356c5d77afd1359cf90a9fdb88bfe7e794 [15] Combined-stimulus pharmacology: GHRH analog (sermorelin class) + ghrelin-receptor agonist (GHRP/ipamorelin class) produces supra-additive GH release; see Ishida et al., 2020 (citation 12) for the modern synthesis of GHRH + GHRP combined-stimulus pharmacology. — https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [16] Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. — https://pubmed.ncbi.nlm.nih.gov/14499707/ [17] Sermorelin acetate drug monograph: FDA approval of sermorelin acetate for pediatric idiopathic GH deficiency (1997); voluntary US market discontinuation (2008) for commercial — not safety — reasons; compounded preparations remain available under 503A/503B framework. — https://www.rxlist.com/sermorelin-acetate-drug.htm [18] Vance ML. Growth-Hormone-Releasing Hormone: A Clinical Update. Ann Intern Med. 1986;105(3):447-454. — https://www.acpjournals.org/doi/10.7326/0003-4819-105-3-447 [19] Yuen KCJ, Biller BMK, Radovick S, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocr Pract. 2019. — https://www.endocrinepractice.org/article/S1530-891X(20)35145-4/fulltext [20] Ratku B, Sebestyén V, Erdei A, et al. Treatment of adult growth hormone deficiency with human recombinant growth hormone: update on current evidence and critical review. Endocrine. 2017. — https://link.springer.com/article/10.1007/s12020-017-1492-1 [21] Bartke A, Brown-Borg H, et al. Growth Hormone in Aging. Endotext (NCBI Bookshelf). Continuously updated. — https://www.ncbi.nlm.nih.gov/books/NBK279163/ [22] Thorner MO, Vance ML. Growth hormone, 1988. J Clin Invest. 1988;82(3):745-747. — https://www.jci.org/articles/view/113673 --- A bioluminescent reading room for the Sermorelin and GHRH (1-29) research record — pulsatile pharmacology read in the dark, cited line by line, and signed by no clinic and no vendor.